Pharmaceutical Technology
MARCH 2, 2023
QN-023a is under clinical development by Hangzhou Qihan Biotechnology and currently in Phase I for Relapsed Acute Myeloid Leukemia. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
pharmaphorum
MAY 7, 2021
Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
FEBRUARY 15, 2022
Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. They also allow genetic material to be added, removed, or altered at particular locations in the genome.
Drug Discovery World
NOVEMBER 27, 2023
Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. Technological innovations supporting discovery and development stages have concentrated on both upstream and downstream aspects of the workflow. This article is sponsored by Revvity.
The Pharma Data
JANUARY 19, 2021
A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well. In bacteria with unaltered tracr-L, levels of CRISPR-related genes were low. The authors found that tracr-L redirects Cas9 in S.
Drug Discovery World
SEPTEMBER 28, 2022
In an advanced stage, 90% of melanoma patients will develop brain metastases,” explained Prof Satchi-Fainaro. Satchi-Fainaro and her team tried to inhibit the expression of the protein and its receptors in genetically engineered lab models and in 3D models of primary melanoma and brain metastases. Corrupted astrocytes . “In
Drug Discovery World
JANUARY 23, 2023
Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. In addition, iPSC lines, despite their pluripotency, have skewed suitability towards certain cell types 12,13.
Expert insights. Personalized for you.
100 
Let's personalize your content